Sacituzumab Govitecan

What Sacituzumab Govitecan Means

Sacituzumab govitecan is a cancer treatment drug that combines a monoclonal antibody with a chemotherapy agent. The antibody part targets a protein called TROP2, which is found on the surface of some cancer cells, especially certain breast cancers. Attached to this antibody is a chemotherapy drug called SN-38, which can damage the DNA of cancer cells and cause them to die. This combination is called an antibody-drug conjugate, meaning it delivers chemotherapy directly to cancer cells, aiming to reduce harm to normal cells.

Why Sacituzumab Govitecan Matters in Cancer Care

This drug is important because it offers a treatment option for adults with advanced breast cancers that are difficult to treat. It is approved for triple-negative breast cancer, a type that does not respond to hormone therapy or HER2-targeted treatments, and for hormone receptor–positive, HER2–negative breast cancer after other therapies have been tried. These cancers have often spread or cannot be removed by surgery. Sacituzumab govitecan provides a targeted way to attack cancer cells, which can be helpful when other treatments have not worked. It is also being studied for other cancers, showing ongoing research interest.

What Patients Might Experience or Hear

Patients may hear the name Trodelvy or sacituzumab govitecan during discussions about treatment options for advanced breast cancer. Doctors may explain that this drug targets cancer cells specifically and delivers chemotherapy directly to them. Patients might be told about possible side effects, which can include nausea, diarrhea, low white blood cell counts, fatigue, and hair loss, among others. Because it can lower white blood cells, patients may be monitored closely for infections. The drug is given through an intravenous (IV) infusion, often on a schedule such as days one and eight of a 21-day cycle.

Where Sacituzumab Govitecan May Appear

You might see sacituzumab govitecan mentioned in your medical records, treatment plans, or reports if you or a loved one is receiving this drug. It may also appear in information about clinical trials or on drug information pages from trusted sources like the National Cancer Institute or MedlinePlus. Knowing that Trodelvy and sacituzumab govitecan refer to the same drug can help avoid confusion when reading different materials.

Common Questions and Considerations

Patients and caregivers may want to ask their care team about how sacituzumab govitecan works, what side effects to expect, and how it fits into the overall treatment plan. It is also important to discuss any other medications being taken to avoid interactions. Since this drug is approved for specific types of breast cancer after other treatments, patients might ask about eligibility and whether clinical trials are available for other cancers. Understanding the monitoring needed during treatment can help patients feel more prepared.

Important Safety and Context Notes

This information is educational and does not replace medical advice. Sacituzumab govitecan can cause serious side effects, including low white blood cell counts and diarrhea, which require careful management by healthcare providers. It may also harm a developing fetus, so pregnancy status should be discussed before treatment. Decisions about using this drug depend on individual health factors and cancer type. Always talk with your healthcare team about what is best for your situation.

Next Steps for Patients and Caregivers

If you come across the term sacituzumab govitecan or Trodelvy in your care, the best next step is to ask your doctor or nurse what it means for your specific treatment. They can explain how this drug might help, what to expect, and how it fits into your overall cancer care plan. Reliable sources like the National Cancer Institute website can also provide helpful information. Remember, your care team is there to support you and answer your questions about any treatment.